Current Issue

Honey's Healing History

admin — Thu, 04 Sep 2008 11:52:09 -0400

Dear Readers,

You know the saying that if you keep something long enough it will come back in style? Well, it appears that the wound care field is not immune to this concept. In this issue, an article by George and Cutting, and a book review by Gethin, focus on the revival of honey as a wound care treatment. The ancient Egyptians used honey as a wound treatment as early as 3000 BC and it has been found in Egyptian tombs.¹ Although it was said to be normal in appearance, I was told that none of the researchers had the courage to taste it. Honey was an integral p

Honey: A Modern Wound Management Product

admin — Thu, 04 Sep 2008 11:52:09 -0400

Honey: A Modern Wound Management Product

Edited by RJ White, RA Cooper, P Molan

Honey:A Modern Wound Management Product is a timely addition to the knowledge base that concentrates on the use of honey in modern wound management. Richard White, Rose Cooper, and Peter Molan—all experts in their respective fields, have made invaluable contribut

Antibacterial Honey: in-vitro Activity Against Clinical Isolates of MRSA, VRE, and Other Multiresistant Gram-negative Organisms

admin — Thu, 04 Sep 2008 11:52:09 -0400

Disclosure: Mr. Cutting has acted as a paid consultancy for Medihoney and Dermasciences.

The media regularly reminds both the public and healthcare professionals of the dangers infection poses to good health, in particular the difficulties in successfully treating infection caused by multiresistant microorganisms.The development of bacterial resistance to antibiotic therapy is understood to be a natural occurrence. The emergence of resistant strains of bacteria and the ensuing management challenges are compounded by the fact that the development of new antibi

Insights on Virulence and Antibiotic Resistance: A Review of the Accessory Genome of Staphylococcus aureus

admin — Thu, 04 Sep 2008 11:52:09 -0400

Staphylococcus aureus has been known as a causative agent of infection since 1882 when Alexander Ogston identified its role in sepsis and abscess formation.¹ It has continued to be one of the most recognized human pathogens throughout the community and hospital settings. S aureus is an opportunistic bacterium, which is frequently part of the human microflora, causing disease when the immune system becomes compromised. Although S aureus can be found in different parts of the body, the anterior nares are the primary ecological niche in humans. Nasal carriage diffe

The Use of Elastocompressive Therapy in a Patient With Acroangiodermatitis of the Lower Limb

admin — Thu, 04 Sep 2008 11:52:09 -0400

Disclosure: This work was supported by the ARRD (Associazione Romana Ricerca Dermatologica).

Acroangiodermatitis is a vasoproliferative disease of the lower limbs associated with congenital or acquired vascular alterations. It is clinically characterized by circumscribed, slowly-evolving, red violaceous or dusky macules, papules, or plaques.^1,2

This condition closely mimics Kaposi’s sarcoma in regard to clinical and histopathological features. For this reason it is also called pseudo-Kaposi sarcoma.¹ Immunolab

Negative Pressure Wound Therapy on Diabetic Foot Ulcers

admin — Thu, 04 Sep 2008 11:52:09 -0400

Reconstruction of diabetic foot ulcers is often a challenging problem. The impairments involved with the healing process, along with the lack of resistance against infection in patients with diabetes, represent a familiar clinical problem.¹ High treatment costs and unsatisfactory results are common.

The surgical treatment of the diabetic wounds with loss of soft tissue continuity usually consists of closure using a split-thickness skin graft or transposition flap. However, immediate surgical closure often fails because surgical closure is not always appropriate given the ge

September 2007

admin — Thu, 04 Sep 2008 11:52:09 -0400

SANUWAVE™ ANNOUNCES APPROVAL FOR DIABETIC FOOT ULCER TREATMENT

SANUWAVE Inc (Alpharetta, Ga), a leading provider and developer of Pulsed Acoustic Cellular Expression (PACE^™) technology, announces the company has received conditional approval from the US Food and Drug Administration (FDA) to initiate a multicenter, prospective, randomized clinical trial utilizing its dermaPACE^™ device for the treatment of diabetic foot ulcers.

The device produces stresses at a cellular level that leads to immediate increases in microcircula

September 2007

admin — Thu, 04 Sep 2008 11:52:09 -0400

Derma Sciences Receives FDA Clearance for API-MED^™

Manuka Honey DressingDerma Sciences (Princeton, NJ), a manufacturer and marketer of advanced wound care products, has received clearance from the US Food and Drug Administration (FDA) to market and sell its API-MED^™ Active Manuka Honey Absorbent dressing. This represents the first FDA clearance of a honey-based product for the management of wounds and burns. Honey-based dressings are noted for their lack of toxicity, ability to be used in all phases of wound healing, as a